Literature DB >> 12533329

Brain metabolite profiles of T1-hypointense lesions in relapsing-remitting multiple sclerosis.

Belinda S Y Li1, Juleiga Regal, Brian J Soher, Lois J Mannon, Robert I Grossman, Oded Gonen.   

Abstract

BACKGROUND AND
PURPOSE: Persistent T1-hypointense lesions ("black holes") are thought to represent permanent damage of brain parenchyma. We attempted to ascertain whether the metabolic profiles of these hypointense areas support this hypothesis and whether these profiles correlate with these hypointense findings.
METHODS: Four patients with relapsing-remitting multiple sclerosis and four matched control volunteers underwent MR imaging and 3D proton MR spectroscopy. Absolute levels of N-acetylaspartate (NAA), creatine, and choline (Cho) were obtained in 0.19 cm(3) voxels containing 14 T1-hypointense lesions (average volume, 0.4 cm(3); range, 0.2-1.0 cm(3)) in patients. Metabolite levels were analyzed, by using Pearson correlation, against their respective lesions' hypointensity relative to the surrounding normal-appearing white matter.
RESULTS: Moderate correlation, r = 0.56, was found between the NAA level and MR imaging hypointensity. Of the 14 lesions studied, 12 were deficient in NAA and 11 had excess Cho compared with corresponding brain regions in control volunteers. Only one lesion was significantly deficient in all three metabolites, indicative of total damage or matrix loss.
CONCLUSION: No relationship was found between the hypointensity of the lesions and their metabolic profile. Specifically, lesions with the same hypointensity on T1-weighted MR images were metabolically variable (ie, displayed disparate metabolite levels and behavior). Also, although 86% of the lesions exhibited abnormally low NAA, 71% also had increased Cho. This indicates that although neuronal damage had already occurred (lower NAA), these lesions were still "smoldering" with active membrane turnover (high Cho), most likely because of de- and remyelination, indicative of shadow plaques (remyelinated lesions). Consequently, relapsing-remitting hypointense lesions represent neither final-stage nor static pathologic abnormality.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12533329      PMCID: PMC8148958     

Source DB:  PubMed          Journal:  AJNR Am J Neuroradiol        ISSN: 0195-6108            Impact factor:   3.825


  40 in total

1.  Quantitative proton MR spectroscopic imaging of the human brain.

Authors:  B J Soher; P C van Zijl; J H Duyn; P B Barker
Journal:  Magn Reson Med       Date:  1996-03       Impact factor: 4.668

Review 2.  Perspectives on multiple sclerosis.

Authors:  R I Grossman; J C McGowan
Journal:  AJNR Am J Neuroradiol       Date:  1998-08       Impact factor: 3.825

Review 3.  In vivo quantitation of metabolite concentrations in the brain by means of proton MRS.

Authors:  O Henriksen
Journal:  NMR Biomed       Date:  1995-06       Impact factor: 4.044

Review 4.  The value of T1-weighted images in the differentiation between MS, white matter lesions, and subcortical arteriosclerotic encephalopathy (SAE).

Authors:  D Uhlenbrock; S Sehlen
Journal:  Neuroradiology       Date:  1989       Impact factor: 2.804

5.  Serial proton MR spectroscopy of contrast-enhancing multiple sclerosis plaques: absolute metabolic values over 2 years during a clinical pharmacological study.

Authors:  I Mader; W Roser; L Kappos; G Hagberg; J Seelig; E W Radue; W Steinbrich
Journal:  AJNR Am J Neuroradiol       Date:  2000-08       Impact factor: 3.825

Review 6.  Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance.

Authors:  F Barkhof; M van Walderveen
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  1999-10-29       Impact factor: 6.237

Review 7.  Natural history of multiple sclerosis.

Authors:  B G Weinshenker
Journal:  Ann Neurol       Date:  1994       Impact factor: 10.422

8.  The concentration of N-acetyl aspartate, creatine + phosphocreatine, and choline in different parts of the brain in adulthood and senium.

Authors:  P Christiansen; P Toft; H B Larsson; M Stubgaard; O Henriksen
Journal:  Magn Reson Imaging       Date:  1993       Impact factor: 2.546

9.  Disability and lesion load in MS: a reassessment with MS functional composite score and 3D fast FLAIR.

Authors:  Olga Ciccarelli; Peter A Brex; Alan J Thompson; David H Miller
Journal:  J Neurol       Date:  2002-01       Impact factor: 4.849

10.  Lesion heterogeneity in multiple sclerosis: a study of the relations between appearances on T1 weighted images, T1 relaxation times, and metabolite concentrations.

Authors:  P A Brex; G J Parker; S M Leary; P D Molyneux; G J Barker; C A Davie; A J Thompson; D H Miller
Journal:  J Neurol Neurosurg Psychiatry       Date:  2000-05       Impact factor: 10.154

View more
  9 in total

1.  Dirty-appearing white matter in multiple sclerosis: volumetric MR imaging and magnetization transfer ratio histogram analysis.

Authors:  Yulin Ge; Robert I Grossman; James S Babb; Juan He; Lois J Mannon
Journal:  AJNR Am J Neuroradiol       Date:  2003 Nov-Dec       Impact factor: 3.825

Review 2.  Imaging of multiple sclerosis: role in neurotherapeutics.

Authors:  Rohit Bakshi; Alireza Minagar; Zeenat Jaisani; Jerry S Wolinsky
Journal:  NeuroRx       Date:  2005-04

3.  (1)H MR spectroscopy of the brain in multiple sclerosis subtypes with analysis of the metabolite concentrations in gray and white matter: initial findings.

Authors:  Paul E Sijens; Jop P Mostert; Matthijs Oudkerk; Jacques De Keyser
Journal:  Eur Radiol       Date:  2005-07-19       Impact factor: 5.315

4.  Characterizing the time course of cerebrovascular reactivity in multiple sclerosis.

Authors:  John A Lincoln; Khader M Hasan; Refaat E Gabr; Jerry S Wolinsky
Journal:  J Neuroimaging       Date:  2022-02-14       Impact factor: 2.324

5.  Clinical and conventional MRI predictors of disability and brain atrophy accumulation in RRMS. A large scale, short-term follow-up study.

Authors:  Sarlota Mesaros; Maria A Rocca; Maria P Sormani; Arnaud Charil; Giancarlo Comi; Massimo Filippi
Journal:  J Neurol       Date:  2008-07-03       Impact factor: 4.849

6.  Total-tau in cerebrospinal fluid of patients with multiple sclerosis decreases in secondary progressive stage of disease and reflects degree of brain atrophy.

Authors:  Jacek Jaworski; Marek Psujek; Marzena Janczarek; Małgorzata Szczerbo-Trojanowska; Halina Bartosik-Psujek
Journal:  Ups J Med Sci       Date:  2012-05-04       Impact factor: 2.384

7.  A rare association between multiple sclerosis and Charcot-Marie-Tooth type 1B.

Authors:  Rosa Cortese; Stefano Zoccolella; Maria Muglia; Alessandra Patitucci; Antonio Scarafino; Damiano Paolicelli; Isabella Laura Simone
Journal:  Brain Behav       Date:  2016-09-25       Impact factor: 2.708

8.  Targeting Cognitive Impairment in Multiple Sclerosis-The Road toward an Imaging-based Biomarker.

Authors:  Jeroen Van Schependom; Guy Nagels
Journal:  Front Neurosci       Date:  2017-06-30       Impact factor: 4.677

Review 9.  Quantifying the Metabolic Signature of Multiple Sclerosis by in vivo Proton Magnetic Resonance Spectroscopy: Current Challenges and Future Outlook in the Translation From Proton Signal to Diagnostic Biomarker.

Authors:  Kelley M Swanberg; Karl Landheer; David Pitt; Christoph Juchem
Journal:  Front Neurol       Date:  2019-11-15       Impact factor: 4.003

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.